Skip to main content

Ameluz News

Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis

Leverkusen, Germany, May 11, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the U.S. Food and Drug Administration (FDA) has g...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Actinic Keratosis

Ameluz patient information at Drugs.com